Scholar Rock (NASDAQ:SRRK) Sees Large Volume Increase After Strong Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) shares saw unusually-high trading volume on Wednesday following a stronger than expected earnings report. Approximately 2,499,630 shares changed hands during mid-day trading, an increase of 148% from the previous session’s volume of 1,008,784 shares.The stock last traded at $44.10 and had previously closed at $44.31.

The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same period in the prior year, the firm earned ($0.64) EPS.

More Scholar Rock News

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Major analysts raised ratings and targets — BMO bumped its target to $70 (Outperform), Citigroup raised its target to $58 (Buy) and Piper Sandler lifted its target to $58 (Overweight), signaling fresh upside expectations. Analyst Price Target Raises Piper Sandler Note
• Positive Sentiment: HC Wainwright raised its FY2030 EPS forecast to $1.26 (from $1.07) and reiterated a Buy rating with a $58 price target — a bullish long‑term earnings view that contrasts with current street estimates. HC Wainwright Upgrade
• Positive Sentiment: Scholar Rock reported progress on apitegromab: management outlined a 2026 BLA resubmission plan and commercial launch preparations following favorable interactions with the FDA — this is the primary operational catalyst for upside if approval and launch proceed. FDA / BLA Progress
• Neutral Sentiment: Q4 2025 results marginally beat expectations (EPS about -$0.88 vs. consensus ~ -$0.8825), showing stability but not a strong inflection in near‑term profitability. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Street consensus still expects a negative EPS for the current fiscal year (≈ -$2.42), underlining that near‑term earnings and cash‑flow risk remain until apitegromab is approved and commercialized. Consensus EPS Context

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Truist Financial lifted their target price on shares of Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday. BMO Capital Markets raised their price target on Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a research report on Wednesday. JPMorgan Chase & Co. lifted their price objective on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Barclays increased their target price on Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average target price of $54.14.

Insiders Place Their Bets

In other Scholar Rock news, insider Mo Qatanani sold 8,484 shares of Scholar Rock stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $47.07, for a total transaction of $399,341.88. Following the transaction, the insider directly owned 98,445 shares in the company, valued at approximately $4,633,806.15. The trade was a 7.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Caryn Parlavecchio sold 9,035 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $420,398.55. Following the completion of the sale, the insider owned 169,087 shares of the company’s stock, valued at $7,867,618.11. This trade represents a 5.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 208,470 shares of company stock worth $9,201,778. 13.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc increased its position in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Scholar Rock in the 4th quarter valued at $30,000. Summit Securities Group LLC acquired a new position in Scholar Rock in the 4th quarter worth $31,000. Ramirez Asset Management Inc. bought a new position in Scholar Rock during the 3rd quarter worth about $37,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares during the period. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Trading Down 2.7%

The company has a quick ratio of 6.30, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $5.30 billion, a P/E ratio of -13.45 and a beta of 0.70. The business has a fifty day moving average price of $45.33 and a 200 day moving average price of $39.19.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).